Alfacalcidol

ইঙ্গিত

Calcium Deficiency

Viva-D is used in adult patients with chronic renal failure to help manage hypocalcemia, secondary hyperparathyroidism, and renal osteodystrophy.

⚠️ কোনো ওষুধ গ্রহণের আগে সর্বদা নিবন্ধিত চিকিৎসকের পরামর্শ নিন।

ফার্মাকোলজি

Alfacalcidol stimulates intestinal calcium and phosphorus absorption, the reabsorption of calcium from bone and possibly the renal reabsorption of calcium. In the majority of patients treated with Alfacalcidol, clinical symptoms of bone pain and muscle weakness begin to remit within 2 weeks to 3 months of the start of therapy. Malabsorption of calcium is rapidly corrected. In patients on daily oral therapy, plasma alkaline phosphatase and PTH levels generally begin to fall within 3 months, but plasma calcium levels may not normalize for several months. This delay should not necessarily be construed as a poor response but may indicate that calcium is being utilized for bone mineralization. The decrease in PTH levels may be more rapid in patients on intermittent intravenous therapy, with significant reductions being achieved within 3 months of therapy.

Pregnancy & Breastfeeding

Alfacalcidol shouldn't be used during pregnancy unless it's clearly needed, since high calcium levels (hypercalcemia) in the mother can lead to congenital problems in the baby. Its safety in pregnant women hasn't been established, and animal studies have shown reproductive toxicity, including lower pregnancy rates, smaller litter sizes, and reduced birth weights. Because Alfacalcidol may pass into breast milk, breastfeeding should be avoided during treatment.

⚠️ Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.

ডোজ নির্দেশিকা

⚠️ শুধুমাত্র সরকারি উৎস থেকে নির্দেশিকা পরিসীমা। ব্যক্তিগতকৃত ডোজের জন্য আপনার ডাক্তারের পরামর্শ নিন।

Adults: Initial dosing for adults starts at 0.25 mcg per day for the first 2 months, unless hypercalcemia develops. If hypercalcemia occurs, the dose should be cut back to 0.25 mcg every other day. If serum calcium stays below the desired range, the dose may instead be increased in steps of 0.25 mcg/day every 2 months. Maintenance doses: most patients are maintained on 0.5 mcg/day, though doses as high as 1 mcg/day may be needed to keep serum calcium within the desired range. Serum calcium and phosphate levels should be checked monthly, or more often if hypercalcemia develops. If hypercalcemia develops at any point during treatment, the alfacalcidol dose should be cut by 50%, and all calcium supplements should be stopped until calcium levels return to normal. Pediatrics: the safety and efficacy of alfacalcidol in children have not been established.

পার্শ্বপ্রতিক্রিয়া ও পারস্পরিক ক্রিয়া

পার্শ্বপ্রতিক্রিয়া

No side-effect data recorded yet.

প্রধান পারস্পরিক ক্রিয়া

Checker →